Cyanotech (CYAN) Getting Somewhat Favorable News Coverage, Report Shows
News coverage about Cyanotech (NASDAQ:CYAN) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cyanotech earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.7123799953135 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Global Astaxanthin Market Investment Report 2016-2021 (reports.pr-inside.com)
- Cardax Refutes Allegations by Competitive Trade Group, NAXA (kait8.com)
- Middle East and Africa Astaxanthin Market is poised to reach USD 65 million by 2021 (reports.pr-inside.com)
- Global $1.22 Billion Astaxanthin Market Outlook 2016-2023 – Rising Demand for Cosmetic Products, Customers Varying Preferences Towards Healthcare & Nutraceutical Products … (businesswire.com)
Several research firms recently commented on CYAN. TheStreet upgraded Cyanotech from a “d” rating to a “c-” rating in a research report on Monday, August 28th. ValuEngine upgraded Cyanotech from a “sell” rating to a “hold” rating in a research report on Monday, August 14th.
Cyanotech (CYAN) remained flat at $$4.30 on Tuesday. The stock had a trading volume of 300 shares, compared to its average volume of 5,447. The company has a market cap of $24.70, a PE ratio of 71.67 and a beta of 1.06. Cyanotech has a 52 week low of $3.25 and a 52 week high of $5.35. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.36 and a quick ratio of 0.72.
Cyanotech (NASDAQ:CYAN) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported $0.08 EPS for the quarter. The company had revenue of $8.06 million during the quarter. Cyanotech had a return on equity of 2.06% and a net margin of 1.11%.
Cyanotech Corporation is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The Company’s products include Hawaiian Spirulina Pacifica and Hawaiian BioAstin. Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids.
Receive News & Ratings for Cyanotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyanotech Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.